Veradermics, Incorporated
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | |
| – | +131.3% | +25.2% | +26.3% | +0.5% | +15.0% | -11.1% | – | |
| – | +43.8% | +18.8% | +29.1% | +114.1% | +85.5% | +22.5% | – | |
| – | +115.7% | +24.8% | +26.6% | +13.1% | +29.8% | -1.0% | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.